VM Oncology, LLC
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
Track VM Oncology, LLC automatically
Every clearance here is in the API, with alerts when new ones post.